Koroscil T M
Endocrinology Service, Wilford Hall USAF Medical Center, Lackland AFB, San Antonio, Tex., USA.
South Med J. 1995 Aug;88(8):831-6. doi: 10.1097/00007611-199508000-00007.
Thionamides are often used acutely to control the symptoms of thyrotoxicosis associated with Graves' disease before definitive treatment with radioiodine. Several reports have suggested that pretreatment with thionamides reduces the efficacy of radioiodine therapy in patients with Graves' disease, but other data refute this. This study retrospectively reviewed the records of 95 patients with Graves' disease treated with radioiodine. Pretreatment with thionamides resulted in significantly greater (2 1/2-fold) treatment failure rate than in patients not pretreated with thionamides but given a comparable dose of radioiodine. Higher serum thyroxine concentration at the time of diagnosis was also an independent factor associated with radioiodine treatment failure.
在使用放射性碘进行确定性治疗之前，硫代酰胺类药物常被急性用于控制与格雷夫斯病相关的甲状腺毒症症状。有几份报告表明，格雷夫斯病患者在放射性碘治疗前使用硫代酰胺类药物预处理会降低其疗效，但其他数据对此予以反驳。本研究回顾性分析了95例接受放射性碘治疗的格雷夫斯病患者的记录。与未使用硫代酰胺类药物预处理但接受相当剂量放射性碘治疗的患者相比，硫代酰胺类药物预处理导致的治疗失败率显著更高（2.5倍）。诊断时较高的血清甲状腺素浓度也是与放射性碘治疗失败相关的独立因素。
